PUBLISHER: The Business Research Company | PRODUCT CODE: 1945407
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945407
Intragastric balloons represent a minimally invasive approach to treating obesity, involving the insertion of a medical implant into the stomach to temporarily reduce its capacity. This method caters to individuals struggling with obesity, offering a non-surgical alternative that bypasses the need for general anesthesia. By occupying space in the stomach, the balloons induce a sensation of fullness, thereby curbing food intake. Typically inserted via an endoscope-a lengthy, flexible tube equipped with a camera-the procedure is performed through the mouth and into the stomach.
The primary variations of intragastric balloons include single, dual, and triple intragastric balloons, each serving as a tool for weight loss among obese patients. These balloons utilize filling materials categorized as saline-filled or gas-filled, and are distributed through various channels including online pharmacies, retail pharmacies, and hospital pharmacies. They find application across diverse areas such as obesity management, diabetes treatment, dietary control, weight reduction prior to surgery, and others. End users encompass hospitals, clinics, ambulatory surgical centers, among others.
Tariffs have created cost pressures in the intragastric balloons market by increasing duties on medical-grade silicone, polymer materials, and endoscopic device components. These impacts have raised manufacturing and procurement costs, particularly affecting silicone-based single and dual balloon systems, with north america and europe experiencing higher exposure due to reliance on imported medical materials. Hospitals and clinics have faced higher procedure costs, influencing patient affordability and adoption rates. On the positive side, tariffs have encouraged local manufacturing, alternative material sourcing, and regional production expansion, supporting long-term supply chain resilience.
The intragastric balloons market research report is one of a series of new reports from The Business Research Company that provides intragastric balloons market statistics, including intragastric balloons industry global market size, regional shares, competitors with a intragastric balloons market share, detailed intragastric balloons market segments, market trends and opportunities, and any further data you may need to thrive in the intragastric balloons industry. This intragastric balloons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The intragastric balloons market size has grown rapidly in recent years. It will grow from $22.05 billion in 2025 to $24.55 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to rising prevalence of obesity worldwide, increasing awareness of weight management solutions, growing limitations of lifestyle-based weight loss methods, expansion of bariatric and endoscopic services, rising preference for minimally invasive treatments.
The intragastric balloons market size is expected to see rapid growth in the next few years. It will grow to $36.1 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for non-surgical obesity treatments, growing incidence of obesity-related comorbidities, rising focus on preventive weight management, expanding availability of endoscopic bariatric procedures, increasing patient preference for reversible weight loss options. Major trends in the forecast period include growing adoption of non-surgical weight loss procedures, rising preference for temporary and reversible bariatric treatments, increasing use of intragastric balloons for pre-operative weight reduction, expansion of intragastric balloon therapy in obesity management programs, growing acceptance of endoscopic weight loss interventions.
The rising rates of obesity are expected to significantly drive the growth of the intragastric balloon market. Obesity, defined by a body mass index (BMI) of 30 or higher, is increasingly prevalent due to factors such as poor dietary habits, sedentary lifestyles, economic conditions, marketing and advertising, genetics, psychological factors, and urbanization. Intragastric balloons offer a non-surgical solution for weight loss by occupying space in the stomach, promoting a feeling of fullness, and reducing food intake, making them an appealing option for those struggling with obesity. According to the World Obesity Atlas 2022, published by the World Obesity Federation, the global economic burden of obesity is projected to reach $4.32 trillion annually by 2035 if current trends continue. By that time, over half of the world's population (51%) could be overweight or obese, with nearly 2 billion individuals, or 1 in 4 people, expected to suffer from obesity. This growing global health challenge is a key driver for the demand for intragastric balloon treatments, further fueling market growth.
Major companies in the intragastric balloon market are developing advanced solutions, including weight loss medications, to address challenges such as dieting difficulties, costs, and fear of surgery. Weight loss medications support body weight reduction by suppressing appetite, enhancing metabolism, or limiting fat absorption. For example, in August 2025, Boston Scientific launched Endura Weight Loss Solutions, providing minimally invasive, endoscopic alternatives to surgery or long-term medication. These solutions include endoscopic sleeve gastroplasty (ESG), which reduces stomach volume by 70-80% through internal stitching, and the Orbera Intragastric Balloon System, which promotes satiety by placing a balloon in the stomach. These outpatient procedures help patients eat less, feel full sooner, and recover quickly, offering a safe and effective option for moderate obesity or patients ineligible for surgery, combined with lifestyle modifications for comprehensive obesity management.
In April 2024, Opus Diagnostics, a Sweden-based technology company, formed a partnership with Gastric Balloon Group. The partnership aims to deliver a non-invasive weight loss solution to the Ascot and Berkshire communities. Gastric Balloon Group is a UK-based company specializing in intragastric balloons for weight loss procedures.
Major companies operating in the intragastric balloons market are Apollo Endosurgery Inc., Allurion Technologies Inc., ReShape Lifesciences Inc., Spatz Medical, USGI Medical Inc., Obalon Therapeutics Inc., Bariatric Solutions International GmbH, Helioscopie SA, Silimed GmbH, Endalis, Medsil, Inamed Health, Micro-Tech (Nanjing) Co. Ltd, EndoShape Inc., Medicone Srl, Medicrea Bariatrics, Ethicon Bariatric Technologies, Endomed Systems GmbH, BaroSense Inc., Endolife Technologies
North America was the largest region in the intragastric balloons market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intragastric balloons market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the intragastric balloons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The intragastric balloons market consists of revenues earned by entities by providing services such as patient evaluation and consultation, nutritional counseling, diagnostic tests, balloon removal, post-removal support, monitoring and follow-up care, and behavioral support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The intragastric balloon market also includes sales of biodegradable intragastric balloons, and adjustable intragastric balloons. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Intragastric Balloons Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses intragastric balloons market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for intragastric balloons ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The intragastric balloons market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.